Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Tuesday.

According to Zacks, “Ekso Bionics Holdings, Inc. is engaged in designing, developing and selling wearable robots or exoskeletons for the medical, military, industrial and consumer markets. The company’s operating segment consists of Engineering Services and Medical segments. It operates primarily in North America, Western Europe, the Middle East and South Africa. Ekso Bionics Holdings, Inc. is headquartered in Richmond, California. “

Separately, B. Riley restated a “buy” rating and issued a $4.00 price target on shares of Ekso Bionics Holdings in a research report on Wednesday, May 10th.

Ekso Bionics Holdings (NASDAQ EKSO) opened at 1.33 on Tuesday. The stock has a 50 day moving average price of $1.82 and a 200-day moving average price of $2.48. Ekso Bionics Holdings has a 12 month low of $0.99 and a 12 month high of $6.38. The stock’s market cap is $34.30 million.

TRADEMARK VIOLATION WARNING: This report was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/08/24/zacks-investment-research-downgrades-ekso-bionics-holdings-inc-ekso-to-hold.html.

In other Ekso Bionics Holdings news, insider Russ Angold sold 28,254 shares of Ekso Bionics Holdings stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $1.53, for a total value of $43,228.62. Following the sale, the insider now owns 250,678 shares of the company’s stock, valued at approximately $383,537.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 7.10% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in EKSO. Intellectus Partners LLC increased its stake in Ekso Bionics Holdings by 5.3% in the second quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock valued at $244,000 after buying an additional 5,294 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Ekso Bionics Holdings by 32.9% in the second quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock valued at $1,650,000 after buying an additional 176,197 shares during the last quarter. National Planning Corp boosted its position in shares of Ekso Bionics Holdings by 116.2% in the second quarter. National Planning Corp now owns 234,450 shares of the company’s stock valued at $537,000 after buying an additional 126,000 shares during the last quarter. Carl Domino Inc boosted its position in shares of Ekso Bionics Holdings by 74.7% in the second quarter. Carl Domino Inc now owns 82,054 shares of the company’s stock valued at $190,000 after buying an additional 35,088 shares during the last quarter. Finally, Independence Advisors LLC bought a new position in shares of Ekso Bionics Holdings during the second quarter valued at $1,840,000. 5.03% of the stock is currently owned by hedge funds and other institutional investors.

Ekso Bionics Holdings Company Profile

Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.

Receive News & Stock Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related stocks with our FREE daily email newsletter.